Patents by Inventor Haoran Zhao

Haoran Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122707
    Abstract: An implant delivery handle, an implant system, a delivery system and a method of use thereof are disclosed. Transmission systems in the implant delivery handle each include a lead screw, an inner tube coupling member, an outer gear and an inner gear. The outer gear rotatably engages the inner gear and is configured to drive rotation of the inner gear. The lead screw is coupled to a first inner tube (11) or a second inner tube (12) through the inner tube coupling member. The lead screw also engages the inner gear and rotates therewith to cause axial movement of the first inner tube (11) or the second inner tube (12). A transmission ratio of the outer gear to the inner gear is greater than 1.
    Type: Application
    Filed: August 15, 2022
    Publication date: April 18, 2024
    Applicants: SHANGHAI TRULIVE MEDTECH CO., LTD., JIANGSU TRULIVE MEDTECH CO., LTD.
    Inventors: Wei ZHANG, Haoran XU, Yongqiang WEI, Jing ZHAO
  • Publication number: 20240115510
    Abstract: The present disclosure provides a testis-targeted lycopene (LYC)/ZIF-90 nanocomposite and a preparation method and use thereof, belonging to the technical field of targeted drugs. In the present disclosure, a ZIF-90 metal-organic framework (MOF) material is combined with LYC through aldol condensation; when entering areas of inflammatory response and oxidative stress response, ZIF-90 may disintegrate and collapse in a slightly-acidic environment, releasing the LYC, thereby avoiding easy oxidation of the LYC and improving a bioavailability of the LYC; in addition, the disintegrated and collapsed ZIF-90 may also be utilized by organisms, thus greatly reducing a damage to the organisms. Moreover, the LYC/ZIF-90 nanocomposite is further loaded with follicle-stimulating hormone (FSH).
    Type: Application
    Filed: December 19, 2022
    Publication date: April 11, 2024
    Inventors: Jinlong LI, Haoran WANG, Muzi LI, Yi ZHAO, Xuenan LI, Lin LIU, Shiyong ZHU
  • Patent number: 11886347
    Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Xi'an Jiaotong University
    Inventors: Tian Xia, Pengju Ren, Haoran Zhao, Zehua Li, Wenzhe Zhao, Nanning Zheng
  • Publication number: 20230297842
    Abstract: A method for event-triggered distributed reinforcement learning for unit commitment optimization and dispatch to solve the waste problem of unit resources includes obtaining a unit commitment optimization and dispatch model, constructing a fixed action set under preset constraint conditions, and selecting optimal power of each unit; transforming constraint conditions into projection constraints, and projecting the virtual generation power to a corresponding constraint range, to obtain actual generation power of each unit within the constraint range; calculating corresponding rewards based on cost under actual generation power of each unit without bandwidth constraints, and updating local Q values of each unit in a Q table according to Q-learning algorithms, to obtain an optimal action of each unit without bandwidth constraints; and under the constraint conditions of considering bandwidths, obtaining an optimal solution, meeting limited bandwidth constraint conditions, to the unit commitment optimization and d
    Type: Application
    Filed: March 21, 2023
    Publication date: September 21, 2023
    Applicant: SHANDONG UNIVERSITY
    Inventors: Shuai LIU, Xiaowen WANG, Haoran ZHAO, Bo SUN, Lantao XING, Xian LI, Ruiqi WANG
  • Publication number: 20220350745
    Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.
    Type: Application
    Filed: July 13, 2022
    Publication date: November 3, 2022
    Inventors: Tian XIA, Pengju REN, Haoran ZHAO, Zehua LI, Wenzhe ZHAO, Nanning ZHENG
  • Publication number: 20200226685
    Abstract: Systems and methods for change in language-based textual analysis are disclosed. In one embodiment, in an information processing apparatus comprising at least one computer processor, a method for change in language-based textual analysis may include: (1) retrieving, from a data source, a first document of a first type; (2) retrieving, from the data source, a second document of the first type, the second document being subsequent in time to the first document; (3) identifying changes between the first document and the second document; (4) calculating a change score based on the changes; and (5) providing the change score to a downstream system for projecting a performance of an investment associated with the first document.
    Type: Application
    Filed: January 15, 2019
    Publication date: July 16, 2020
    Inventors: Phil Hart, Jonathan Tse, Santosh Khot, Dan Zheng, Manan Patel, Wonseok Choi, Haoran Zhao, Dennis S. Ruhl, Eric Moreau
  • Patent number: 9453028
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 27, 2016
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Publication number: 20150376203
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Patent number: 9149475
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 6, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu, Carlos Valdez, Jing Zhang, Emily Stauffer, Matthew Duncton, Salvador Alvarez
  • Patent number: 9095593
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: August 4, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Patent number: 8993585
    Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: March 31, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Donald Payan, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu
  • Patent number: 8394951
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 12, 2013
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Patent number: 8377924
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: February 19, 2013
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Rajinder Singh, HuĂ­ Li, Haoran Zhao, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu, Carlos Valdez, Jing Zhang, Emily Stauffer, Matthew Duncton, Salvador Alvarez
  • Patent number: 8314093
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: November 20, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jeffrey Wayne Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Publication number: 20100204208
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 21, 2010
    Publication date: August 12, 2010
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu, Carlos Valdez, Jing Zhang, Emily Stauffer, Matthew Duncton, Salvador Alvarez
  • Publication number: 20100184755
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 13, 2010
    Publication date: July 22, 2010
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Publication number: 20100152172
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Application
    Filed: December 18, 2009
    Publication date: June 17, 2010
    Inventors: Jeffrey W. Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Publication number: 20100130486
    Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
    Type: Application
    Filed: July 17, 2008
    Publication date: May 27, 2010
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Donald Payan, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu
  • Patent number: 7659280
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: February 9, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jeffrey Wayne Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Patent number: 7521192
    Abstract: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: April 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: X. Charlene Liao, Esteban Masuda, Peter Chu, Jorge Pardo, Congfen Li, Haoran Zhao, Ying-Ping Jiang, Collin Spencer